These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 9398709)

  • 1. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus.
    Yki-Järvinen H; Ryysy L; Kauppila M; Kujansuu E; Lahti J; Marjanen T; Niskanen L; Rajala S; Salo S; Seppälä P; Tulokas T; Viikari J; Taskinen MR
    J Clin Endocrinol Metab; 1997 Dec; 82(12):4037-43. PubMed ID: 9398709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC; Tsang LW; Sorensen JP; Cockram CS
    Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive insulin therapy combined with metformin in obese type 2 diabetic patients.
    Fritsche A; Schmülling RM; Häring HU; Stumvoll M
    Acta Diabetol; 2000 Mar; 37(1):13-8. PubMed ID: 10928231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM.
    Cusi K; Cunningham GR; Comstock JP
    Diabetes Care; 1995 Jun; 18(6):843-51. PubMed ID: 7555511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.
    Kelley DE; Bray GA; Pi-Sunyer FX; Klein S; Hill J; Miles J; Hollander P
    Diabetes Care; 2002 Jun; 25(6):1033-41. PubMed ID: 12032111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
    DeFronzo RA; Goodman AM
    N Engl J Med; 1995 Aug; 333(9):541-9. PubMed ID: 7623902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects.
    Ozata M; Gungor D; Turan M; Ozisik G; Bingol N; Ozgurtas T; Ozdemir IC
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3659-64. PubMed ID: 11502793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
    Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
    Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
    Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS
    Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of different insulin regimens in elderly patients with NIDDM.
    Wolffenbuttel BH; Sels JP; Rondas-Colbers GJ; Menheere PP; Nieuwenhuijzen Kruseman AC
    Diabetes Care; 1996 Dec; 19(12):1326-32. PubMed ID: 8941458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.
    Hollander PA; Elbein SC; Hirsch IB; Kelley D; McGill J; Taylor T; Weiss SR; Crockett SE; Kaplan RA; Comstock J; Lucas CP; Lodewick PA; Canovatchel W; Chung J; Hauptman J
    Diabetes Care; 1998 Aug; 21(8):1288-94. PubMed ID: 9702435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Avilés-Santa L; Sinding J; Raskin P
    Ann Intern Med; 1999 Aug; 131(3):182-8. PubMed ID: 10428734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.
    Miles JM; Leiter L; Hollander P; Wadden T; Anderson JW; Doyle M; Foreyt J; Aronne L; Klein S
    Diabetes Care; 2002 Jul; 25(7):1123-8. PubMed ID: 12087008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
    Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y
    Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors.
    Chow CC; Ko GT; Tsang LW; Yeung VT; Chan JC; Cockram CS
    Diabetes Care; 1997 Jul; 20(7):1122-7. PubMed ID: 9203448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
    Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
    Meneghini LF; Traylor L; Schwartz SL
    Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is type 2 diabetes a different disease in obese and nonobese patients?
    Prando R; Cheli V; Melga P; Giusti R; Ciuchi E; Odetti P
    Diabetes Care; 1998 Oct; 21(10):1680-5. PubMed ID: 9773730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.
    Fujishima Y; Maeda N; Inoue K; Kashine S; Nishizawa H; Hirata A; Kozawa J; Yasuda T; Okita K; Imagawa A; Funahashi T; Shimomura I
    Cardiovasc Diabetol; 2012 Sep; 11():107. PubMed ID: 22973968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM.
    Anfossi G; Mularoni EM; Burzacca S; Ponziani MC; Massucco P; Mattiello L; Cavalot F; Trovati M
    Diabetes Care; 1998 Jan; 21(1):121-6. PubMed ID: 9538982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.